161 related articles for article (PubMed ID: 23519920)
1. Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative.
Passarelli MN; Newcomb PA; LaCroix AZ; Lane DS; Ho GY; Chlebowski RT
J Bone Miner Res; 2013 Sep; 28(9):2043-8. PubMed ID: 23519920
[TBL] [Abstract][Full Text] [Related]
2. Oral bisphosphonate use and lung cancer incidence among postmenopausal women.
Tao MH; Chen S; Freudenheim JL; Cauley JA; Johnson KC; Mai X; Sarto GE; Wakelee H; Boffetta P; Wactawski-Wende J
Ann Oncol; 2018 Jun; 29(6):1476-1485. PubMed ID: 29617712
[TBL] [Abstract][Full Text] [Related]
3. Oral bisphosphonate use and risk of postmenopausal endometrial cancer.
Newcomb PA; Passarelli MN; Phipps AI; Anderson GL; Wactawski-Wende J; Ho GY; O'Sullivan MJ; Chlebowski RT
J Clin Oncol; 2015 Apr; 33(10):1186-90. PubMed ID: 25713431
[TBL] [Abstract][Full Text] [Related]
4. Oral bisphosphonate use and breast cancer incidence in postmenopausal women.
Chlebowski RT; Chen Z; Cauley JA; Anderson G; Rodabough RJ; McTiernan A; Lane DS; Manson JE; Snetselaar L; Yasmeen S; O'Sullivan MJ; Safford M; Hendrix SL; Wallace RB
J Clin Oncol; 2010 Aug; 28(22):3582-90. PubMed ID: 20567009
[TBL] [Abstract][Full Text] [Related]
5. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative.
Drieling RL; LaCroix AZ; Beresford SA; Boudreau DM; Kooperberg C; Chlebowski RT; Gass M; Crandall CJ; Womack CR; Heckbert SR
Menopause; 2016 Nov; 23(11):1168-1175. PubMed ID: 27433859
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
[TBL] [Abstract][Full Text] [Related]
7. Chocolate Candy and Incident Invasive Cancer Risk in the Women's Health Initiative: An Observational Prospective Analysis.
Greenberg JA; Neuhouser ML; Tinker LF; Lane DS; Paskett ED; Van Horn LV; Wassertheil-Smoller S; Shikany JM; Qi L; Sealy-Jefferson S; Manson JE
J Acad Nutr Diet; 2021 Feb; 121(2):314-326.e4. PubMed ID: 32763064
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative.
Drieling RL; LaCroix AZ; Beresford SAA; Boudreau DM; Kooperberg C; Chlebowski RT; Ko MG; Heckbert SR
J Am Geriatr Soc; 2017 Sep; 65(9):1924-1931. PubMed ID: 28555811
[TBL] [Abstract][Full Text] [Related]
9. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
Pazianas M; Abrahamsen B; Eiken PA; Eastell R; Russell RG
Osteoporos Int; 2012 Nov; 23(11):2693-701. PubMed ID: 22392160
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of bisphosphonate use and risk of colorectal cancer.
Khalili H; Huang ES; Ogino S; Fuchs CS; Chan AT
J Clin Oncol; 2012 Sep; 30(26):3229-33. PubMed ID: 22649131
[TBL] [Abstract][Full Text] [Related]
12. Exposure to oral bisphosphonates and risk of cancer.
Cardwell CR; Abnet CC; Veal P; Hughes CM; Cantwell MM; Murray LJ
Int J Cancer; 2012 Sep; 131(5):E717-25. PubMed ID: 22161552
[TBL] [Abstract][Full Text] [Related]
13. Reproductive and menstrual factors and colorectal cancer incidence in the Women's Health Initiative Observational Study.
Murphy N; Xu L; Zervoudakis A; Xue X; Kabat G; Rohan TE; Wassertheil-Smoller S; O'Sullivan MJ; Thomson C; Messina C; Strickler HD; Gunter MJ
Br J Cancer; 2017 Jan; 116(1):117-125. PubMed ID: 27898658
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
15. Racial differences in colorectal cancer incidence and mortality in the Women's Health Initiative.
Simon MS; Thomson CA; Pettijohn E; Kato I; Rodabough RJ; Lane D; Hubbell FA; O'Sullivan MJ; Adams-Campbell L; Mouton CP; Abrams J; Chlebowski RT
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1368-78. PubMed ID: 21602308
[TBL] [Abstract][Full Text] [Related]
16. Exposure to oral bisphosphonates and risk of esophageal cancer.
Cardwell CR; Abnet CC; Cantwell MM; Murray LJ
JAMA; 2010 Aug; 304(6):657-63. PubMed ID: 20699457
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature.
Liu Y; Zhao S; Chen W; Hu F; Zhu L; Zhang Q; Zhao Y
Clin Breast Cancer; 2012 Aug; 12(4):276-81. PubMed ID: 22622199
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein(a) plasma levels, bone mineral density and risk of hip fracture: a post hoc analysis of the Women's Health Initiative, USA.
Haring B; Crandall CJ; Carbone L; Liu S; Li W; Johnson KC; Wactawski-Wende J; Shadyab AH; Gass ML; Kamensky V; Cauley JA; Wassertheil-Smoller S
BMJ Open; 2019 Apr; 9(4):e027257. PubMed ID: 31023762
[TBL] [Abstract][Full Text] [Related]
19. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
Hue TF; Cummings SR; Cauley JA; Bauer DC; Ensrud KE; Barrett-Connor E; Black DM
JAMA Intern Med; 2014 Oct; 174(10):1550-7. PubMed ID: 25111880
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
